Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Power List / 2022 / Small Molecules / Edward Haeggstrom

Edward Haeggström

CEO, Nanoform

  • Profile

Meet Edward Haeggström

In 2015, Haeggström commercialized the nanoparticle engineering platform he developed with Jouko Yliruusi, acting professor at the University of Helsinki, Finland. This marked the beginning of Nanoform. When asked about what could improve the pharma industry, he responded, “The shift toward a more patient-centric approach in the design of new drugs is something that has been gaining momentum and which I am keen to see more of in the pharma industry. It is my belief that it is not only patients who stand to gain from therapies more tailored to their needs, but also a chance for pharma to grow from both a commercial and humanitarian standpoint. Wider adoption of patient-centric practices and incorporation of patients’ feedback from the early stages of drug discovery through to development has the potential to revolutionize patients’ quality of life. In today’s ever more technologically advanced world, it is easier than ever to achieve.”

False

Advertisement

Recommended

False

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.